Tango Therapeutics and Fractyl Health Cut Jobs to Narrow Their Focus

Two Greater Boston drug developers announced job cuts this week, adding to a run of Boston biotech layoffs this fall. Burlington-based Fractyl Health said on Oct. 22 it will cut about 45% of its workforce to focus on its Revita weight-maintenance procedure, and Boston-based Tango Therapeutics said on Oct. 23 it will cut about 14% of its staff, mostly in research, to concentrate on its lead cancer drugs. Both companies disclosed the plans in filings with the Securities and Exchange Commission.

Fractyl Health: about 45% of staff, done by November

Fractyl (Nasdaq: GUTS) said its board adopted the plan on Oct. 21. The reduction affects about 45% of the company’s headcount, which the Boston Business Journal put at about 45 employees, and is expected to be substantially complete by November 2026. In its Form 8-K, the company estimated about $2 million in severance and related charges, mostly in the fourth quarter.

The key numbers from Fractyl’s announcement:

• Cash runway: existing cash is expected to fund operations into the second quarter of 2027.
• Cash burn: quarterly operating cash burn is expected to fall by about 50%, to about $8 million, by the end of the second quarter of 2027.
• Pipeline: the company is ending internal development of its Rejuva gene therapy program and is seeking “strategic alternatives” for it.
• Leadership: co-founder Jay Caplan will retire as president and chief product officer effective Oct. 30 and stay on as a senior advisor. CEO Harith Rajagopalan will also take the title of president.

The cuts follow six-month results from the REMAIN-1 pivotal study, which Fractyl said met its six-month co-primary endpoint on weight regain compared with a sham procedure. Revita is an endoscopic procedure aimed at people trying to keep weight off after stopping GLP-1 drugs. Fractyl’s stated timeline is an FDA De Novo submission in late 2026, 12-month pivotal data in the first quarter of 2027, a possible FDA decision in late 2027 and a possible U.S. launch in early 2028.

Tango Therapeutics: about 14%, mostly research staff

Tango (Nasdaq: TNGX), whose offices are at 201 Brookline Ave. in Boston’s Longwood area, said its board approved a “strategic reprioritization” on Oct. 22. The company will cut about 14% of its workforce, mostly from its research group, stop some preclinical and research work, and step back from discovering new drug targets. BioSpace noted Tango reported 137 full-time employees, including 97 in research and development, at the end of 2025, which would put the cut at roughly 19 people. The company did not give a number.

Tango will focus on PRMT5-targeted cancer drugs, its clinical candidates vopimetostat and TNG456. On the same day, it reported updated Phase 1/2 results for vopimetostat combined with Revolution Medicines’ daraxonrasib in pancreatic cancer at the ESMO 2026 Congress in Madrid. As of an Aug. 20 data cutoff, the company reported an 82% objective response rate and an 88% nine-month progression-free survival rate in 22 evaluable patients with previously treated MTAP-deleted, RAS-mutant pancreatic cancer.

Tango said it plans to start a global registrational trial comparing the combination with standard chemotherapy in newly diagnosed MTAP-deleted pancreatic cancer in the first half of 2027. It also plans to start a Phase 1/2 study of vopimetostat with a RAS inhibitor in second-line pancreatic cancer without the MTAP deletion in the first half of 2027, and intends to discuss a possible second-line approval path with regulators.

A pattern across the region

The two announcements are part of a broader trend of Massachusetts life sciences companies shrinking to stretch cash and focus on their most advanced programs. We covered the wider picture, including empty lab space, in our report on Kendall Square biotech layoffs and lab vacancies. Health care employers are also cutting: see our story on Mass General Brigham’s latest layoffs.

The overall job market has held up better than the biotech sector. The Massachusetts unemployment rate was 4.3% in September 2026, down from 4.6% a year earlier, according to Bureau of Labor Statistics data published by FRED. More local company news is collected in the Boston business and economy section of our Boston News hub.

What the companies said

“While these decisions are difficult, particularly those impacting our colleagues, we believe this focused strategy will position Fractyl to operate more efficiently and advance Revita toward its clinical and commercial potential,” Rajagopalan said in the company’s release.

On an investor call, Tango CEO Malte Peters said the company expects to seek FDA guidance on a possible accelerated approval path for the combination, BioSpace reported. BioSpace also noted that the 82% response rate was lower than the 92% Tango reported in June, when fewer patients had been evaluated.

Featured image: The Longwood Medical Area in Boston, near Tango Therapeutics’ Brookline Avenue offices. Photo by SBAmin via Wikimedia Commons, CC BY-SA 3.0, cropped.

Sources

• Fractyl Health press release (SEC Exhibit 99.1), Oct. 22, 2026
• Fractyl Health Form 8-K, filed Oct. 22, 2026
• Boston Business Journal: Burlington biotech cuts nearly half its staff
• Tango Therapeutics press release, Oct. 23, 2026
• Tango Therapeutics Form 8-K, filed Oct. 23, 2026
• BioSpace Layoff Tracker: Tango plans 14% workforce cut
• FRED: Unemployment Rate in Massachusetts (MAUR)